Carbohydrate (i.e., Saccharide Radical Containing) Doai Patents (Class 514/23)
  • Patent number: 10668086
    Abstract: The invention relates to a capsule consisting of a shell and a filling, which contains plant sterol ester and/or plant stanol ester and emulsifier. The capsule is suitable for lowering serum LDL cholesterol level.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: June 2, 2020
    Assignee: RAISIO NUTRITION LTD
    Inventors: Päivi Kuusisto, Ingmar Wester, Leena Koponen, Jari Ekblom, Jouni Niemela
  • Patent number: 10647737
    Abstract: A synthetic charged glycolipid is described comprising a sulfated saccharide group covalently linked to the tree sn-1 hydroxyl group of the glycerol backbone of an archaeal core lipid via a beta linkage. The synthetic charged glycolipids include compounds of formula I wherein n is 0 or 1; R is hydrogen or hydroxyl; and Y is hydrogen or a sulfate group, at least one Y being a sulfate group; and including pharmaceutically acceptable salts thereof. The sulfated glycolipid produces stable archaeosomes at a mol % ratio of from 100:0 to 30:70 (sulfated glycolipid:uncharged glycolipid) and which induce a protective immune response, including CD8+ and CD4+ T cell responses. Archaeosomes comprising the sulfated glycolipids described have desirable adjuvant properties, particularly when mixed with uncharged glycolipid at a mol % ratio of about 50:50.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: May 12, 2020
    Assignee: National Research Council of Canada
    Inventors: Dennis M. Whitfield, G. Dennis Sprott, Lakshmi Krishnan
  • Patent number: 10633372
    Abstract: The present invention relates to an improved process for the preparation of amorphous (1S)-1,5-anhydro-1-[3-[[5 -(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol compound of formula-1, represented by the following structural formula.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: April 28, 2020
    Assignee: MSN LABORATORIES PRIVATE LIMITED
    Inventors: Srinivasan Thirumalai Rajan, Sajja Eswaraiah, Chakilam Nagaraju, Achampeta Kodanda Ramprasad, Peri Seetha Rama Sarma, Boge Rajesham
  • Patent number: 10624875
    Abstract: The invention relates to methods and compositions for treating schizophrenia or bipolar disorder (in particular, mania) by using a combination of a synaptic vesicle protein 2A (SV2A) inhibitor and an antipsychotic or their pharmaceutically acceptable salts, hydrates, solvates, polymorphs thereof. In some embodiments, the methods and the compositions are for treating one or more positive and/or negative symptoms, as well as cognitive impairment, associated with schizophrenia or bipolar disorder (in particular, mania).
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: April 21, 2020
    Assignee: The Johns Hopkins University
    Inventors: Michela Gallagher, Ming Teng Koh
  • Patent number: 10624859
    Abstract: Disclosed in certain embodiments is a system and method of providing a dronabinol oral solid dosage form with increased stability.
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: April 21, 2020
    Assignee: Rhodes Technologies
    Inventor: Robert J. Kupper
  • Patent number: 10617694
    Abstract: There is provided for novel therapy of sleep apnea that involves administering the drug sultiame to the patient.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: April 14, 2020
    Inventors: Jan Hedner, Ludger Grote, Kaj Stenlöf
  • Patent number: 10576137
    Abstract: The invention relates to methods of producing, and compositions comprising, an isolated alpha (2?8) or (2?9) oligosialic acid derivative bearing a non-reducing end enriched for one or more de-N-acetyl residues and resistant to degradation by exoneuraminidase. A representative production method involves: (i) treating an alpha (2?8) or (2?9) oligosialic acid precursor having a reducing end and a non-reducing end with sodium borohydride under conditions for de-N-acetylating the non-reducing end; and (ii) isolating alpha (2?8) or (2?9) oligosialic acid derivative having one or more de-N-acetylated residues and a non-reducing end that is resistant to degradation by exoneuraminidase. Isolated alpha (2?8) or (2?9) oligosialic acid derivatives that comprise a non-reducing end de-N-acetyl residue are provided, as well as antibodies specific for the derivatives, compositions comprising the derivatives, kits, and methods of use including protection against and detection of E. coli K1 and N.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: March 3, 2020
    Assignee: Children's Hospital Research Center at Oakland
    Inventors: Gregory R. Moe, Brent T. Hagen
  • Patent number: 10568919
    Abstract: The present invention discloses a composition and use. The composition comprises hemp seed oil and algal oil with a mass ratio of (20˜60):(30˜70). After a large number of screening studies on concerted application, the present inventors found that the composition has synergistic effects, specifically, it has significant inhibitory effects on weight gain of animal model rats for hyperlipidemia, can significantly increase the hypolipidemic efficacy, and has an anti-oxidation effect. In addition, the composition of the present invention has efficacies of improving learning and memory abilities, improving constipation, and protecting the liver. Medicaments and functional food made from the composition of the present invention are simple in production process, stable in product quality, clear in functional factor, prominent in health care efficacy, low in administration dosage, safe in use, without toxic and side effects, and are suitable for consumption of the general population.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: February 25, 2020
    Assignee: INFINITUS (CHINA) COMPANY LTD.
    Inventors: Zehua Chen, Jialing Ning, Chung Wah Ma, Yiting Yang, Fang Ma
  • Patent number: 10561623
    Abstract: The present invention provides compositions and methods of their use in treating muscular dystrophy and other disorders.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: February 18, 2020
    Assignee: The Charlotte Mecklenburg Hospital Authority
    Inventor: Qi Long Lu
  • Patent number: 10556877
    Abstract: The present invention relates to a process for the preparation of amorphous dapagliflozin. The present invention relates to 2,3-butanediol solvate of dapagliflozin and process for its preparation.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: February 11, 2020
    Assignee: Glenmark Life Sciences Limited
    Inventors: Shekhar Bhaskar Bhirud, Kumar Hari Bhushan, Raghu Ram Suraparaju, Nandkumar Gaikwad, Sharad Gore, Rajendra Jagdhane, Mandar Kulkarni
  • Patent number: 10538547
    Abstract: The present invention provides a mangiferin-6-O-calcium salt and a preparation process thereof. In addition, use of the mangiferin-6-O-calcium salt as defined in claim 1 as an intermediate in the preparation of a mangiferin-6-O-berberine salt is also provided.
    Type: Grant
    Filed: December 25, 2018
    Date of Patent: January 21, 2020
    Assignee: CHANGZHOU DEZE MEDICAL SCIENCE CO., LTD
    Inventors: Houlei Teng, Wei Wu
  • Patent number: 10533032
    Abstract: Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: January 14, 2020
    Assignee: THERACOS SUB, LLC
    Inventors: Mengzhuang Cai, Qian Liu, Ge Xu, Binhua Lv, Brian Seed, Jacques Roberge
  • Patent number: 10525078
    Abstract: A solid dialysis A agent is provided, which is to be used in preparing a bicarbonate dialysis fluid, wherein: the solid dialysis A agent contains glucose, acetic acid and an acetate salt; at least a part of a mixture of the acetic acid with the acetate salt is an alkali metal diacetate; and the acetic acid/acetate salt molar ratio is adjusted to 1/0.5 to 1/2. This solid dialysis A agent makes it possible to prepare a bicarbonate dialysis fluid which has a total acetate ion concentration of 2 to less than 6 mEq/L. Further, the dialysis A agent exhibits excellent stability of ingredients and a reduced acetic acid odor.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: January 7, 2020
    Assignee: Tomita Pharmaceutical Co., Ltd.
    Inventors: Michiko Myose, Hiroshi Noguchi, Junya Kikuishi, Hideyuki Aoyama, Mina Hashimoto, Yusuke Yoshimoto
  • Patent number: 10500175
    Abstract: The present invention discloses anti-cancer compositions, and associated methods, including an anti-cancer composition comprising: a cellular energy inhibitor having the structure according to formula I wherein X is selected from the group consisting of: a nitro, an imidazole, a halide, sulfonate, a carboxylate, an alkoxide, and amine oxide; and R is selected from the group consisting of: OR?, N(R?)2, C(O)R??, C1-C6 alkyl, C6-C12 aryl, C1-C6 heteroalkyl, a C6-C12 heteroaryl, H, and an alkali metal; where R? represents H, alkali metal, C1-C6 alkyl, C6-C12 aryl or C(O)R??, R? represents H, C1-C6 alkyl, or C6-C12 aryl, and R?? represents H, C1-C20 alkyl or C6-C12 aryl. The anti-cancer composition can additionally comprise at least one sugar, which stabilizes the cellular energy inhibitor by substantially preventing the inhibitor from hydrolyzing. Also, the anti-cancer composition can comprise a hexokinase inhibitor.
    Type: Grant
    Filed: December 26, 2017
    Date of Patent: December 10, 2019
    Assignee: KODISCOVERY, LLC
    Inventor: Young Hee Ko
  • Patent number: 10478446
    Abstract: Polycystic kidney disease is a cystic genetic disorder of the kidneys. Recent identification of signaling cascades de-regulated in PKD has led to the initiation of several clinical trials, but an effective therapy is still lacking. A new therapeutic paradigm is capable of improving the proliferation rate and cystic kidney volume in PKD.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: November 19, 2019
    Assignees: FONDAZIONE CENTRO SAN RAFFAELE OFFICE OF BIOTECHNOLOGY TRANSFER, FONDAZIONE TELETHON
    Inventors: Alessandra Boletta, Marco Chiaravalli, Isaline Severine Marie-Josephe Rowe
  • Patent number: 10457671
    Abstract: The invention relates to a new crystalline form of Canagliflozin of formula I, with its systematic name (2S,3R,4R,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl) methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol5 and a method of its preparation.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: October 29, 2019
    Assignee: Zentiva k.s.
    Inventors: Josef Zezula, Peter Babiak, Ondrej Dammer
  • Patent number: 10391044
    Abstract: The present disclosure provides low water dentifrice compositions comprising an effective amount of a zinc ion source, a stannous ion source, a polyphosphate and an acid in a calcium pyrophosphate base. The acid lowers the pH of the composition to enable stabilization of the metal ions and extend shelf-life of the composition.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: August 27, 2019
    Assignee: Colgate-Palmolive Company
    Inventors: Kavita Vemishetti, Linh Fruge, Michael Prencipe
  • Patent number: 10369163
    Abstract: Compositions and foods which contain (1) histidine and (2) vitamin B6 and/or carnosine are useful for treating, improving, and recovering from fatigue.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: August 6, 2019
    Assignee: AJINOMOTO CO., INC.
    Inventors: Tetsuro Shibakusa, Mayu Sugita
  • Patent number: 10342867
    Abstract: The present invention relates to a family of carbohydrate monosulphate fatty acid esters, which contain less than 10 mole % of carbohydrate polysulphate fatty acid esters, and to a method of preparation thereof. The monosulphate carbohydrate esters according to the invention comprise one sulphate ester and at least one fatty acid and are among others useful as adjuvants for immunological products such as vaccines.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: July 9, 2019
    Assignee: LITEVAX B.V.
    Inventors: Lucas A. Th. Hilgers, Peter Paul L. I. Platenburg, Johannes F. Van Den Bosch
  • Patent number: 10327678
    Abstract: Embodiments of the invention provide analyte sensors having optimized elements and/or configurations of elements as well as methods for making and using such sensors. Typical embodiments of the invention include glucose sensors used in the management of diabetes.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: June 25, 2019
    Assignee: Medtronic MiniMed, Inc.
    Inventors: Rebecca K. Gottlieb, Rajiv Shah, Eric A. Larson, Chia Chiu
  • Patent number: 10307352
    Abstract: A composition including water, about 0.1% to about 0.4% of a 4-substituted resorcinol, an ester having at least about 25 carbon atoms, and a polymeric emulsifier is provided. The composition comprises less than about 5% by weight of oils and is substantially free of monomeric emulsifier. Methods of treating the skin are also provided.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: June 4, 2019
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Marisa DeVita Dufort, Simarna Kaur, Michael D. Southall, Ping Wen, Jeffrey M. Wu
  • Patent number: 10293054
    Abstract: In some embodiments, a lipofullerene-saccharide compound and a method of inhibiting and/or ameliorating metastasis of neoplastic cells using said compound is disclosed herein. The lipofullerene-saccharide compound may be used in therapeutically effective doses to inhibit the metastasis of neoplasms in mammals. In some embodiments, the method may include administering to a subject an effective amount of a pharmaceutically acceptable formulation including a lipofullerene-saccharide compound. In some embodiments, the lipofullerene-saccharide compound may be formed by reacting (e.g., coupling) a lipid and a saccharide with a fullerene. In some embodiments, neoplastic cells may include pancreatic cancer cells, prostate cancer cells, lung cancer cells, breast cancer cells, colon cancer cells, and/or brain cancer cells.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: May 21, 2019
    Assignee: LivePet, LLC
    Inventors: Ian Mitchell, Ayyappan Subbiah, Daniel David Bensimon
  • Patent number: 10292635
    Abstract: A method of assessing the likelihood that an individual has impulse control disorder. The individual is provided with an actuator, and instructed to actuate the actuator as an acknowledgement of when the individual has completed a reward task. Actuation of the actuator is monitored and recorded. An automated diagnosis of ICD is produced and output, wherein a greater degree of actuation of the actuator by the individual is taken to indicate a greater likelihood that the individual has impulse control disorder.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: May 21, 2019
    Assignee: Global Kinetics Pty Ltd
    Inventors: Robert Irwin Griffiths, Malcolm Kenneth Home, Andrew H. Evans
  • Patent number: 10292382
    Abstract: Methods and processes for cryopreservation and direct cell thawing and seeding or suspension after cryopreservation, including methods that eliminate the necessity of post-thaw wash, spin, and frequent practice of performing a cell count. Cell compositions and no-spin cell products produced using the methods are also described.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: May 21, 2019
    Assignee: Biopredic International Sarl
    Inventors: Belkacem Bouaita, Sandrine Camus, Nathalie Rougier, Ruo Ya Li, Christophe Chesne, David M. Steen
  • Patent number: 10285969
    Abstract: The present invention provides a mangiferin-6-O-berberine salt and a preparation method thereof, and further provides a use of the mangiferin-6-O-berberine salt for the treatment of diabetics and other diseases as an AMPK activator.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: May 14, 2019
    Assignees: CHANGZHOU DEZE MEDICAL SCIENCE CO., LTD
    Inventors: Houlei Teng, Wei Wu, Jingzhuo Zhang, Zhe Lin
  • Patent number: 10278948
    Abstract: A novel method for treating pain conditions, impulse control conditions, and also for treating obesity may include transnasally delivering topiramate or a pharmaceutical salt thereof to the sphenopalatine ganglion of a patient. This method of delivery will provide effective treatment of one or more of obesity, epileptic seizure, intracranial hypertension, glaucoma, altitude sickness, cystinuria, periodic paralysis, central sleep apnea, dural ectasia, fibromyalgia, neuropathic pain, central pain syndrome, nicotine addiction, alcohol addiction, cocaine addiction, and/or for enhancing or effecting cocaine-ingestion reduction, binge-eating reduction, and/or reduction of incidence of migraine headache onset, with an effective dosage amount that is a small fraction of known effective oral dosages.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: May 7, 2019
    Inventor: Tian Xia
  • Patent number: 10258647
    Abstract: The present invention generally relates to iron-polysaccharide (polydextrose) complexes and methods for the preparation thereof. In particular, the present invention relates to iron-polydextrose complexes and methods for the preparation thereof. The inventive complexes are suitable for use in various compositions, including particulate compositions that may be incorporated in various forms of administration, including tablets, capsules, and intravenous formulations. The complexes and compositions of the present invention are suitable for use in the treatment of iron deficient anemia. Advantageously, in addition to providing iron supplementation the complexes and compositions of the present invention provide certain advantages based on the presence of polydextrose (e.g., its low glycemic index and high fiber content).
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: April 16, 2019
    Assignee: PARTICLE DYNAMICS INTERNATIONAL, LLC
    Inventors: Paul Brady, Keith Cromack
  • Patent number: 10251904
    Abstract: Provided are methods for treating Arenaviridae and Coronaviridae virus infections by administering nucleosides and prodrugs thereof, of Formula I: wherein the 1? position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: April 9, 2019
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Michael O'Neil Hanrahan Clarke, Joy Yang Feng, Robert Jordan, Richard L. Mackman, Adrian S. Ray, Dustin Siegel
  • Patent number: 10253281
    Abstract: A method of washing textile articles can be carried out, for example, in a continuous batch tunnel washer. Embodiments of the present method can include treating the textile with an aqueous composition including cleaning agent and halogen-containing bleaching agent for a time sufficient to remove soil from the textile and contacting the halogen-treated textile with an aqueous composition including a peroxycarboxylic acid. The concentration of halogen after the sufficient time can be at a level that does not result in adverse interaction between the halogen-containing bleaching agent and the peroxycarboxylic acid. Embodiments of the present method can clean textiles with the results of more effective stain removal and less waste through destruction of the textile article. Further, the present invention can clean a textile contacted soiled by a composition including chlorhexidine gluconate without resulting staining of the textile, which staining could have been permanent.
    Type: Grant
    Filed: August 20, 2012
    Date of Patent: April 9, 2019
    Assignee: Ecolab USA Inc.
    Inventors: Russell Shawn Berman, Max Donald Harper, Joel Monroe Madenwald, Carl Henry Mattson
  • Patent number: 10251898
    Abstract: Provided are compounds, methods, and pharmaceutical compositions for treating Filoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula IV: The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: April 9, 2019
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Byoung Kwon Chun, Michael O'Neil Hanrahan Clarke, Edward Doerffler, Hon Chung Hui, Robert Jordan, Richard L. Mackman, Jay P. Parrish, Adrian S. Ray, Dustin Siegel
  • Patent number: 10245231
    Abstract: The present invention relates to a novel dry acid concentrate (DAC) for a dialysis liquid and to a dialysis liquid, which is made from said concentrate, and which may be used for purifying blood. The invention further relates to a method of making the dry acid concentrate as well as the dialysis liquid. It also relates to a container (10) comprising said acid concentrate, and which is—in certain embodiments—specially adapted to a dialysis unit.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: April 2, 2019
    Assignee: Fresenius Medical Care Deutschland GmbH
    Inventors: Thierry Eyrard, Philippe Laffay, Benoit Luaire
  • Patent number: 10246476
    Abstract: A method for producing high purity D-psicose crystals having a purity of 98% (w/w) or more and a grain size of MA200 or more. The method includes: removing impurities from a D-psicose solution to obtain a purified D-psicose solution; concentrating the purified D-psicose solution; cooling the concentrated D-psicose solution to 30° C. to 40° C. through a heat exchanger; seed crystallizing the D-psicose solution at 30° C. to 40° C. to obtain a seed crystallized massecuite; and full-scale crystallizing the seed crystallized massecuite. The method can produce pure D-psicose crystals in a suitable form for industrial application through an economical crystallization process from the D-psicose solution without using organic solvents.
    Type: Grant
    Filed: August 9, 2015
    Date of Patent: April 2, 2019
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Seong Bo Kim, Seung Won Park, Jun Gap An, Joo Hang Lee
  • Patent number: 10245277
    Abstract: The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including Type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat, inhibit or reduce the likelihood of hepatitis viral infections, including Hepatitis B and Hepatitis C viral infections, as well as the secondary disease states and/or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, among other disease states or conditions.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: April 2, 2019
    Assignees: VOLANT HOLDINGS GMBH, THERABRAKE, INC.
    Inventors: Joseph M. Fayad, Jerome Schentag
  • Patent number: 10242852
    Abstract: The invention relates to the detection of fatty acids. In a particular aspect, the invention relates to methods for detecting very long chain fatty acids and branched chain fatty acids by mass spectrometry.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: March 26, 2019
    Assignee: Quest Diagnostics Investments Incorporated
    Inventor: Scott Goldman
  • Patent number: 10226439
    Abstract: The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: March 12, 2019
    Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., UNIVERSITY OF SOUTH FLORIDA, UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: James Turkson, Said M. Sebti, Wayne Guida, Man Lun Yip, Nicholas Lawrence, Harshani Rithma Lawrence, Benjamin Greedy
  • Patent number: 10213452
    Abstract: The present invention relates to pharmaceutical compositions containing steviol glycoside and or steviol glycoside derivatives as well as to their use as osmotics in particular for use in the treatment of chronic renal failure by dialysis.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: February 26, 2019
    Assignee: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH
    Inventors: Abelardo Isaac Aguilera Peralta, Manuel Lopez-Cabrera, Rafael Selgas Gutierrez, Sonja Steppan, Jutta Passlick-Deetjen
  • Patent number: 10202623
    Abstract: An object of the present invention is to provide a series of techniques for producing 1,4-butanediol from methanol or the like. Provided is a recombinant cell prepared by introducing a gene encoding at least one enzyme selected from the group consisting of succinate semialdehyde dehydrogenase, succinyl-CoA synthase, CoA-dependent succinate semialdehyde dehydrogenase, 4-hydroxybutyrate dehydrogenase, 4-hydroxybutyryl-CoA transferase, 4-hydroxybutyryl-CoA reductase, 4-hydroxybutyraldehyde dehydrogenase, and alcohol dehydrogenase, into a host cell which is a methylotroph, wherein the gene is expressed in the host cell, and the recombinant cell is capable of producing 1,4-butanediol from at least one C1 compound selected from the group consisting of methane, methanol, methylamine, formic acid, formaldehyde, and formamide.
    Type: Grant
    Filed: January 20, 2014
    Date of Patent: February 12, 2019
    Assignee: SEKISUI CHEMICAL CO., LTD.
    Inventors: Masahiro Furutani, Akihiro Uenishi, Koichiro Iwasa
  • Patent number: 10201179
    Abstract: An energy composition includes a methylated xanthine, a choline derivative, and at least one flavorant in a sufficient amount to render the energy composition palatable. The energy composition may also include vitamins, amino acids, enzymes, preservatives, and the like.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: February 12, 2019
    Assignee: International IP Holdings LLC
    Inventor: Manoj Bhargava
  • Patent number: 10195227
    Abstract: Described are methods for using cyclodextrin to treat, inhibit, prevent, ameliorate, or cure diabetes or conditions relating to diabetes.
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: February 5, 2019
    Assignee: L&F Research LLC
    Inventors: Alessia Fornoni, Sandra Merscher-Gomez
  • Patent number: 10183053
    Abstract: Multi-component formulations comprise methylsulfonylmethane, fructose 1,6-diphosphate, and just one of trehalose, green tea extract, ashwagandha, and rutin, or a combination thereof. Multi-component formulations can prevent, delay, or treat cognitive decline, Alzheimer's disease, and other dementias.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: January 22, 2019
    Inventor: Gene S. Rosen
  • Patent number: 10183038
    Abstract: Assays, methods and kits for predicting a subject's (e.g., human) risk of primary glomerulopathy, secondary glomerulopathy or recurrence (e.g., post-transplant recurrence) of any glomerular disease include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Assays for predicting if a diabetic subject will develop kidney disease or a patient with FSGS will develop recurrent disease after transplant also include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Also described herein are compositions and methods for treating and preventing the aforementioned disorders.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: January 22, 2019
    Assignee: L&F Research LLC
    Inventors: Alessia Fornoni, Sandra Merscher-Gomez
  • Patent number: 10182998
    Abstract: The present disclosure provides a novel pharmaceutical composition for treating a malignant pleural effusion (MPE), including a benzenesulfonamide derivative and a pharmaceutically acceptable excipient. The present disclosure further provides a method for treating MPE by using the pharmaceutical composition.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: January 22, 2019
    Assignee: Gongwin Biopharm Holdings Co., Ltd.
    Inventors: Chuan-Ching Yang, Mao-Yuan Lin
  • Patent number: 10174010
    Abstract: The present invention relates to canagliflozin Monohydrate and its crystalline forms, which as compared to the prior art, have higher stability in water or aqueous system, are more suitable for wet granulation processes or suspension preparations and have good storage stability; the present invention also relates to preparation methods of canagliflozin Monohydrate and its crystalline forms, pharmaceutical compositions thereof and uses thereof in preparation of drugs for treating diseases such as diabetes, diabetes complications, obesity and so on.
    Type: Grant
    Filed: July 4, 2014
    Date of Patent: January 8, 2019
    Assignee: HANGZHOU PUSHAI PHARMACEUTICAL TECHNOLOGY CO., LTD.
    Inventors: Xiaoxia Sheng, Xiaohong Sheng, Kun Zhao, Xiaoye Song
  • Patent number: 10165792
    Abstract: The hunger minimized fasting system relies on providing a blood glucose level at all times in the range of 5 to 10 mM, satisfying glucose needs of the brain and metabolizing blood glucose through anaerobic glycolysis to release ATP at the extramitocontrial portion of the cell. Consuming only solid free nutrient liquids eliminates brain hunger response. Liquids consumed during fasting include solid filtered vegetable soup and clear fruit juices of 8 to 12 ounces taken every 2 to 4 hours having calorie deficiency of 600 to 1400 as compared to minimal daily calorie requirements for an adult. Fat released from storage is metabolized by ATP produced by glycolysis at the extramitocontrial location and enters the interior of the mitochondria, enabling the TCA cycle. Weight loss observed during fasting is about one half to one pound per day.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: January 1, 2019
    Inventors: Sudarshan Narasimhan, Dave Narasimhan
  • Patent number: 10117834
    Abstract: The present invention provides compositions, methods for lyophilizing compounds and making pharmaceutical compositions, and kits providing solutions and lyophilized formulations of compounds. The compositions, methods, and kits are particularly useful in pharmaceutical applications involving therapeutic agents that have low solubility at low pH and medium pH values. Certain embodiments provide methods for lyophilizing compounds in liquid solutions, which include the steps of: a) preparing aqueous solutions of a compound of interest in the absence of buffer; b) adjusting the pH to high values of pH in order to increase the solubility of the compound of interest; and c) freeze-drying the solution to provide a lyophilized solid composition. Aqueous solutions including buffer are also disclosed. Lyophilized formulations, including micronized and non-micronized powders, are provided.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: November 6, 2018
    Assignee: BIOGEN CHESAPEAKE LLC
    Inventor: Sven Jacobson
  • Patent number: 10093616
    Abstract: Methods for preparing intermediates of SGLT2 inhibitors are provided, including crystalline forms and methods of crystallizing intermediates.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: October 9, 2018
    Assignee: THERACOS SUB, LLC
    Inventors: Jacques Roberge, Carine Vaxelaire, Baohu Liu, Ge Xu, Jian Zhang, Xinxing Tang, Baihua Xu
  • Patent number: 10092495
    Abstract: The invention concerns a use of C7 sugars and derivatives of formula (I), called avocado perseose, which have, inter alia, a protective activity to epidermal skin cells. These C7 sugars and derivatives are capable of maintaining the expression of markers of adult stem cells, in particular basal stem cells. Avocado perseose can also be used for preventing the deleterious effects of environmental damage. Avocado perseose has a beneficial effect on the conservation of the potential of epidermal stem cells and thus helps maintain skin homeostasis.
    Type: Grant
    Filed: February 11, 2014
    Date of Patent: October 9, 2018
    Assignee: LABORATOIRE EXPANSCIENCE
    Inventors: Philippe Msika, Caroline Baudouin
  • Patent number: 10076131
    Abstract: The present invention generally relates to the field of nutrition. In particular the present invention relates to infant nutrition in the post natal period and in early life, more particular during the age period of 6-36 months or during a part thereof. One embodiment of the present invention is a kit of diet compositions for children during the age period of 6-36 months or during a part thereof, wherein the macronutrient content of the compositions is gradually changing in the form of a straight line from a composition that comprises about 40-50% energy from fat and about 40-49% energy from carbohydrates for children at the age of 6 months to a composition that comprises about 30-35% energy from fat and about 50-55% energy from carbohydrates for children at the age of 36 months, and its use to prevent obesity later in life.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: September 18, 2018
    Assignee: Nestec S.A.
    Inventors: Yasaman Shahkhalili, Kevin Acheson, Katherine Mace, Julie Moulin, Irene Zbinden, Olivier Aprikian, Theresa Voss
  • Patent number: 10071032
    Abstract: Compositions and methods of treating and/or preventing conditions of the oral cavity, e.g. gingivitis, comprise applying a toothpaste composition comprising at least 5% sodium chloride in a toothpaste base comprising a zinc salt, non-silica calcium carbonate abrasive and humectant, to the oral surfaces, e.g., the teeth and gums, of a patient in need thereof.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: September 11, 2018
    Assignee: Colgate-Palmolive Company
    Inventors: Yun Xu, Dorathy Zeng, Kahn Tan, Pingdong Li
  • Patent number: 10071057
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: September 11, 2018
    Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder